Good evening, and thank you for joining Bio-Rad Laboratories' 2022 Earnings Results Conference Call. My name is Daniel, and I will be your moderator for today. I will now hand the conference over to our host, Edward Chung, Head of Investor Relations at Bio-Rad. Edward, you may proceed.

Thanks, Daniel. Good afternoon, and thank you all for joining us. Today, we will review the third quarter 2022 financial results and provide an update on key business trends for Bio-Rad. On the call with me today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Simon May, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I'd like to caution everyone that we will be making forward-looking statements about management's goals, plans, and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are commentary regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share, which are financial measures that are not defined under Generally Accepted Accounting Principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. With that, I will now turn the call over to Ilan Daskal, our Executive Vice President and Chief Financial Officer.

Thank you, Ed. Good afternoon, and thank you all for joining us. Before I begin the detailed third quarter discussion, I would like to ask Andy Last, our Chief Operating Officer, to provide an update on Bio-Rad's global operations. Andy?

Right. Thank you very much, Ilan. So as the world continued its recovery from the pandemic, we experienced strong demand for both our Life Science and Clinical Diagnostic products, and our organization is broadly back to normal operations. We also had modestly higher-than-expected demand for COVID-related products, particularly in Asia Pacific. However, improvement in product supply in the quarter was slower to materialize than we expected, which negatively impacted sales across several product lines, particularly early in the quarter, and we continue to carry a significant order backlog. As previously mentioned, the areas of challenge have been primarily electronic components for instruments. We did experience improved product supply as the quarter progressed, and we now see a positive improvement trend for product supply as we enter the fourth quarter. In addition, during the quarter, we experienced significantly elevated logistics costs and ongoing higher cost in raw materials. Inventory levels increased quarter-to-quarter, reflecting strength in demand and the order backlog as we focus on procuring the remaining key components. During the quarter, we launched our next-generation Droplet Digital PCR system QX600, which brings advanced 6 color-based multiplexing and application flexibility, especially in oncology and reproductive health to our customers. We are extremely pleased with the market response and have quickly built a strong order book. Also in Q3, we completed the acquisition of Curiosity Diagnostics and their PCR-1 system. This system provides a sample-to-answer, high multiplex, and rapid diagnostic PCR system to facilitate our entry into the molecular disease testing market with a differentiated platform. Integration of this Warsaw, Poland-based company is progressing very smoothly. While relatively small, our business operations in Russia continued to be challenging as a result of increased sanctions and employee concerns over the military draft mandate. We expect sanctions to continue to impact operations for the near to medium term. Overall, we are very pleased with our performance in China, although the protracted Zero COVID policy had some extended effect on our Clinical and Life Science businesses in Q3, and we see the recovery to normal taking a little longer. In closing, as we enter Q4, our organization continues to focus on resolving the supply chain challenges, which importantly have already begun to ease, reducing our backlog and meeting the high levels of demand we are experiencing from our customers. Thank you. And I’ll now pass you back to Ilan.

Thank you, Andy. Now I would like to review the results of the third quarter. Net sales for the third quarter of 2022 were $680.8 million, which is an 8.9% decline on a reported basis versus $747 million in Q3 of 2021. The third quarter decline in revenue was mainly a result of lower COVID-related sales this year as well as the receipt of a one-time $32 million settlement for bank royalties from 10x in the year-ago period. On a currency-neutral basis, revenue declined 4.1%. We estimate that COVID-related sales were $17 million in the quarter and continued to reflect an elevated level of demand, particularly in Asia as a result of the ongoing outbreaks in China. Year-over-year core revenue, which excludes COVID-related sales and the 10x $32 million settlement in the third quarter of 2021, increased 6.1% on a currency-neutral basis. On a geographic basis, we experienced currency-neutral year-over-year core revenue growth in Europe and Asia. Core revenue in the Americas was largely flat as a result of the supply chain constraints that we have been experiencing in the past year. As Andy mentioned earlier, we continue to carry an elevated order backlog as a result of supply chain constraints and continued strong customer demand. We are now seeing higher production volumes and anticipate reductions of order backlog through the remainder of this year. Sales of the Life Science Group in the third quarter of 2022 were $317.9 million compared to $373.5 million in Q3 of 2021, which is a 14.9% decline on a reported basis and an 11% decline on a currency-neutral basis. Excluding last year's 10x settlement, the Life Science Group sales declined 6.9% on a reported basis and a 2.3% decline on a currency-neutral basis. Despite supply chain constraints, the underlying Life Science year-over-year currency-neutral core revenue growth was 9.4%. The year-over-year growth was primarily driven by Western loading, qPCR, process media and our antibody products. We continue to see a strong order backlog for ddPCR instruments as we continue to work through the supply chain challenges. I will highlight that ddPCR consumables continue to post strong double-digit growth. During the third quarter, we launched the QX600 ddPCR system as previously communicated. While not material to the third quarter results, the initial market reception for the QX600 has been encouraging, and we are seeing a strong order pipeline building. Process Media, which can fluctuate on a quarterly basis, continues to experience solid year-over-year growth, and we continue to expect strong double-digit growth for the franchise for the full year of 2022. Excluding Process Media sales and last year's 10x settlement, the underlying Life Science business declined 4.2% on a currency-neutral basis versus Q3 of 2021 due to lower COVID-related sales. When also excluding COVID-related sales, revenue growth was 9.6% on a currency-neutral basis. On a geographic basis, Life Science experienced currency-neutral year-over-year core revenue growth in Europe and Asia and was relatively flat in the Americas. Sales of the Clinical Diagnostics Group in the third quarter were $361.9 million compared to $372.2 million in Q3 of 2021, which is a 2.8% decline on a reported basis and growth of 3% on a currency-neutral basis. Core Clinical Diagnostics year-over-year growth, which excludes COVID-related sales, increased 3.7% on a currency-neutral basis despite headwinds from sporadic lockdowns in China. The Diagnostics Group currency-neutral year-over-year increase was primarily driven by quality control, blood typing, and infectious disease products. And as I mentioned earlier, supply chain constraints had an impact on instrument placements. Despite the supply chain constraints impacting the instrument placements, we experienced increased consumables volume for diagnostics driven by strong recovery in routine testing markets. As such, we believe that we are positioned to benefit from the strong underlying market dynamics in the coming quarters. On a geographic basis, the Diagnostics Group year-over-year currency-neutral core revenue grew in the Americas and Asia and declined in Europe. The reported gross margin for the third quarter of 2022 was 54.9% on a GAAP basis and compares to 58.6% in Q3 of 2021. Recall that in the third quarter of 2021 included $32 million from a legal settlement that benefited gross margin in the year-ago period. The year-over-year gross margin decline was also impacted by significantly higher logistics and material costs, lower COVID sales as well as overall product mix. These headwinds were partially offset by a positive currency impact due to the strong dollar and continued operational efficiencies achieved through the restructuring efforts. While we have implemented price increases to address inflationary costs, the realized price capture has only been a partial offset due to our instrument backlog situation. Amortization related to prior acquisitions recorded in cost of goods sold was $4.4 million, as compared to $4.7 million in Q3 of 2021. SG&A expenses for Q3 of 2022 were $211 million, or 31% of sales compared to $216.2 million or 28.9% in Q3 of 2021. The year-over-year SG&A expenses decreased mainly due to the stronger dollar and normalized employee-related benefits but was partially offset by higher discretionary spending. Total amortization expense related to acquisitions recorded in SG&A for the quarter was $1.8 million versus $2.4 million in Q3 of 2021. Research and Development expense in the third quarter was $69.9 million or 10.3% of sales compared to $64.5 million or 8.6% of sales in Q3 of 2021. The year-over-year R&D expenses increased mainly due to project spending. Q3 operating income was $92.8 million or 13.6% of sales compared to $156.8 million or 21% in Q3 of 2021. Looking below the operating line, the change in fair market value of equity securities holdings which are substantially related to Bio-Rad's ownership of Sartorius AG shares negatively impacted the reported results by $289 million. During the quarter, interest and other income resulted in net other expense of $13 million compared to net other expense of $3.2 million last year. Q3 of 2022 included about $8 million of interest and foreign currency expense and $5 million of expense related to an investment impairment. The effective tax rate for the third quarter of 2022 was 21.5% compared to 21.8% for the same period in 2021. The effective tax rate reported in Q3 of 2022 was primarily affected by the unrealized loss in equity securities and the tax rate reported in Q3 of 2021 was primarily affected by an unrealized gain in equity securities. Reported net loss for the third quarter was $164.2 million and the diluted loss per share was $5.52 compared to $3.928 billion of net income and $129.96 per share in Q3 of 2021. This decrease from last year is largely related to changes in the valuation of the Sartorius Holdings. Moving on to the non-GAAP results. Looking at the results on a non-GAAP basis, we have excluded certain atypical and unique items that impacted both the gross and operating margins as well as other income. These items are detailed in the reconciliation table in the press release. Looking at the non-GAAP results for the third quarter. In cost of goods sold, we have excluded $4.4 million of amortization of purchased intangibles and $1.3 million of restructuring costs. These exclusions moved the gross margin for the third quarter of 2022 to a non-GAAP gross margin of 55.7% versus 57.9% in Q3 of 2021. Non-GAAP SG&A in the third quarter of 2022 was 30% versus 29.6% in Q3 of 2021. In SG&A, on a non-GAAP basis, we have excluded restructuring expense of $2.8 million and in vitro diagnostic registration fee in Europe for previously approved products of $2.2 million, amortization of purchased intangibles of $1.8 million and a small legal related benefit. Non-GAAP R&D expense in the third quarter of 2022 was 10.2% versus 9% in Q3 of 2021. In R&D, on a non-GAAP basis, we have excluded $500,000 of restructuring costs. The cumulative sum of these non-GAAP adjustments results in moving the quarterly operating margin from 13.6% on a GAAP basis to 15.5% on a non-GAAP basis. This non-GAAP operating margin compares to a non-GAAP operating margin of 19.4% in Q3 of 2021. We have also excluded certain items below the operating line, which are the decreasing value of Sartorius equity securities and loan receivable holdings of $289 million and a $6.6 million loss associated with venture investments. The non-GAAP effective tax rate for the third quarter of 2022 was 21.6% compared to 18% for the same period in 2021. The higher rate in 2022 was driven by geographical mix of earnings as well as a decrease in compensation-related tax deductions. And finally, non-GAAP net income for the third quarter of 2022 was $77.9 million or $2.60 diluted earnings per share compared to $112.2 million and $3.71 per share in Q3 of 2021. Moving on to the balance sheet. Total cash and short-term investments at the end of Q3 were $1.856 billion compared to $1.973 billion at the end of Q2 of 2022. Inventory at the end of Q3 reached $685.9 million from $657.1 million in the prior quarter. The increase was the result of the ongoing supply chain constraints. For the third quarter of 2022, net cash generated from operating activities was $7.5 million, which compares to $230.4 million in Q3 of 2021. These lower quarterly operating cash flow mainly reflects the changes in the operating results and in working capital. During the third quarter, we completed the acquisition of Curiosity Diagnostics for a total consideration of up to $170 million, consisting of approximately $100 million in cash and up to $70 million in future milestones. During the third quarter, we did not purchase any shares of our stock. The adjusted EBITDA for the third quarter of 2022 was $132.3 million or 19.4% of sales. The adjusted EBITDA in Q3 of 2021 was $165.1 million or 23.1% of sales. Net capital expenditures for the third quarter of 2022 were $24.1 million, and depreciation and amortization was $32.7 million. Moving on to the non-GAAP guidance. Taking into account the strong customer demand, we maintain the full year currency-neutral revenue growth outlook to be at the high end of our guidance range of 1% to 2%. Based on the stronger-than-anticipated COVID sales contribution year-to-date, we now assume full year COVID-related sales of about $105 million. Core revenue growth, which excludes COVID-related sales and the prior year legal settlement for bank royalties is now expected to be about 8%. We anticipate full year core growth for the Life Science group to be about 15% and the Diagnostics group to be approximately 3%. As a result of the ongoing supply chain constraints, we now anticipate a full year gross margin projection to be about 57% versus our prior guidance of 57.5%. Operating income margin guidance remains at about 19% as we manage our operating expense plan for the remainder of this year. We now project adjusted EBITDA at the low end of our prior guidance range of 24% and 24.3%. We continue to execute on our overall capital allocation model, which includes acquisitions such as Curiosity, and we will continue to be opportunistic with share buybacks. I'll now turn over the call to Norman to make a few comments regarding our capital allocation strategy. Norman?

Thanks, Ilan. I thought it would be useful to take a few minutes to address the recent rumors of a potential transaction with one of our peers. While I'm not going to comment on the speculation, I do think it would be helpful to reinforce our thinking around capital deployment in general. Our primary focus, as we stated a number of times, is investing in the organic growth strategy, most recently communicated at our Investor Day in the first quarter of this year. In this regard, we have solid R&D investment levels in the 9% to 10% range. We are also investing to improve our channel reach and capabilities to allow us to grow in our key targeted markets. Additionally, we have multiple initiatives in process focused on building our systems and operational capabilities to support this growth. The next area of investment for us is, of course, inorganic opportunities, acquiring new products or technologies to further our strategy and at the end of the day, make us more valuable to our customers. Over the last several years, these have been smaller or medium-sized acquisitions, which over time have contributed to about one-third of our growth, if you look back. In all cases, we've given careful consideration to the strategic, financial, and operational fit. It's clear that we've made a lot of operational progress in recent years. We now feel we could acquire and absorb a larger and more transformational opportunity, if it met our strategic and financial metrics. The third capital deployment avenue for us is buying back our own shares. Even though we did not buy anything back in this last quarter, we have been active here over the last few years. And today, we have about $300 million authorized by the board for this purpose. I think the point is that we see all three of these as important elements of an overall capital allocation strategy. So that really concludes our prepared remarks today, and we'll now open up the line to take your questions.

The first question comes from Patrick Donnelly of Citi.

Norman, I’d like to follow up on your comments about capital allocation. I appreciate your insights. Given the three-pronged approach you mentioned, could we delve deeper into the larger deals? You've mentioned that those tend to be opportunistic and rare. How do you currently view the pipeline? Additionally, how do you see the Sartorius stake in terms of leveraging it for a deal compared to its strategic value as we assess the landscape?

Yes. I don’t believe the landscape has changed significantly in the past several months; it remains largely the same. As we have mentioned before, opportunities are rare. However, we continue to explore what may be possible. When considering all of this, we still view Sartorius as very strategic, and as you know, we have about five or six years left on the trust. So we have some time to consider our options.

When considering a potential deal, if you didn't opt for Sartorius and pursued a significant acquisition instead, you mentioned previously being open to using some equity, particularly if the valuation is below $400. Are you experiencing any reluctance to issue a substantial amount of equity given the current share valuation? What are your thoughts on that aspect?

Well, I think it certainly depends on what the opportunity is, and I think we have to look at it holistically. We've got obviously, three elements that we can think about. We've got cash on the balance sheet. We've got debt capacity. And then I would say we are comfortable with some economic dilution using equity. But obviously, we're going to be careful and prudent with all of that.

Okay. That's helpful. So moving on from the capital allocation side. Ilan, maybe on the kind of near term here, just looking at the gross margin piece, can you just talk about, I guess, the headwinds you saw there? It seems like logistics, some raw materials. Can you just talk about, I guess, the visibility into the improvement there for, obviously, you adjusted the guidance a little bit? But just maybe the moving pieces there and how we should think about that as we get into 4Q and then even into '23.

Sure. Thank you, Patrick. I appreciate the question. Yes, so when we look at the third quarter, definitely logistics was a headwind and with our normalized kind of level of spend, but it was kind of interrelated somewhat also to the supply chain constraints. So there were still constraints in terms of specifically electronic components, as Andy mentioned in the prepared remarks. And there was also some mix within kind of the revenue itself. On a positive note, our manufacturing cost in terms of the FX was a little bit of a tailwind in terms of the overall cost there. As Andy mentioned earlier, we see an improvement, and our guidance also bakes in a nice improvement in terms of the overall supply chain. We do see an increased volume that is being manufactured constantly and incrementally, so that also will benefit the logistics cost overall. We are very encouraged because the overall order backlog is still nice, although it's going down, but customers are still holding up. Logistics cost part of it, for example, was expedited shipments because customers do come first for us. So obviously, when it comes to the fourth quarter, we can see that the order backlog is still a nice size, although it's going down with the higher volume that we are able to manufacture.

That's helpful. I have one last question regarding the fourth quarter guidance. Even with a slight reduction in the non-core, or non-COVID area, it's still suggesting a significant increase in growth in the fourth quarter, potentially reaching the teens. Is this primarily due to the easing of supply chain issues and the progress in reducing the backlog? Can you provide some insight into your visibility regarding the supply chain improvement? Are you seeing those changes already? Additionally, how much of the backlog do you anticipate being able to address and convert in the fourth quarter to meet those projections?

Yes, Patrick, it's Andy. So yes, I think we mentioned in the script that we're already seeing it easing. We were more constrained at the beginning of the quarter than as we came out of the quarter and now entering into Q4, we see our production improving. So I think that's our expectation right now is we will meaningfully work down a significant piece of our backlog as we get to the end of the year. We still expect to have some backlog as we move into the first quarter of next year, but we do expect improvement, and we do have the visibility on the production at this point in time.

Our next question comes from Brandon Couillard of Jefferies.

Maybe a question for Simon. You did mention ddPCR is one of the standout growth drivers in the press release. Curious if you see any deceleration of growth in that category? Was there perhaps some customers waiting for the QX600 launch? And if you can just talk about the types of customers or markets that that platform will open up would be helpful.

Yes. Thanks for the question, Brandon. We definitely had a few customers, I'd say, waiting for the launch of QX600. I'd say the quarter overall was a bit of a mixed bag for the franchise. We've heard already on the call that the supply chain challenges was a headwind in the third quarter and particularly with instrument platforms. I think in ddPCR, we felt that a little more prominently than some of the other product lines. At the same time, as we've heard already, demand remains strong across multiple application segments, and we're very happy with the launch of the QX600 and the initial pipeline that we're building and seeing for that. So, I think in the quarter as a whole, the puts and saves kind of net out across multiple market segments. And as we enter Q4, we're cautiously confident of a rebound.

Got you. And then maybe one for Ilan. In terms of just back on the gross margins in the third quarter, any way to quantify the logistics and freight and other items in terms of the year-over-year impact on gross margins in the quarter?

Sure. Logistics was by far the highest kind of headwind. And the offset was somewhat the foreign exchange benefit throughout the global manufacturing footprint costs. And mix was probably the third kind of thing. But in terms of order of logistics was first.

Got you. And you could share what that pricing realization was in the third quarter, and you mentioned some of that has been the capture is not quite what you put through in terms of the list price increases. Should we expect that to step up materially in the fourth quarter into the magnitude?

Yes, this is Andy. So we have a modest price realization through year-to-date, but clearly not sufficient to overcome all of the inflationary costs here, especially since we have quite a backlog and below that backlog is being carried for a while now. So kind of pre-price increases. As our backlog unwinds, we do expect to capture more of what we've put into our price increases. And so we're hopeful that Q4 will see some improvement as we roll in through the quarter.

Lastly, just on the Curiosity Diagnostics acquisition in the quarter. Is there any revenue associated with that business? If not, you can talk about commercial timelines and maybe just the competitive differentiation of the multiplex platform versus others that are on the market?

Sure. Thanks, Brandon. This is Dara. The platform is still in the pre-commercial stage, indicating that it's more about acquiring technology. There's significant work ahead to finish the assay development and clinical trials. It will enter regulated markets, so we do not expect any substantial contributions next year. It will likely extend beyond the 2023 timeline as we proceed with the development investment. In general, it is a rapid multiplex sample-to-answer PCR platform, and we will initially focus on applications related to syndromic infectious diseases. There are several features in their approach that set it apart from other products. We believe it will also allow us to reach additional market segments that are not currently addressed by existing syndromic testing platforms. We look forward to providing more updates on this as the year progresses.

The next question comes from Dan Leonard of Credit Suisse.

I have a couple. The first one on the supply chain challenges. Are they influencing at all your win rate in Digital PCR or any other market categories? Do you feel like you're still winning your entitlement and just absorbing the products in backlog?

I think we would say that we're mostly absorbing this in backlog; it's hard to claim that there's not a few months here and there. I think there are, inevitably, especially on the more commoditized product areas. But the size of our backlog has built through the year, and now we're working it down. So we've been very supported by basically customer loyalty to our product offerings. So that contributes a little bit to our elevated logistics costs in Q3 as we were really expediting shipments to them so a lot more in Q3 if this product did come off the production line. So yes, that's essentially, I think, how we see it right now.

Understood. And then just a couple of follow-up on capital deployment. Ilan, does that uncertainty that Bio-Rad might be deemed an investment company under the Investment Company Act I guess two questions. Has that been resolved? And then secondly, if it hasn't, does that have any impact on your ability to finance an acquisition?

Thanks for the question. We have never considered ourselves to be an investment company, and that remains true. This is not a barrier for any potential acquisition or any aspect of capital allocation, whether related to our debt, capital issuance, or equity, that would prevent us from pursuing opportunities.

And possibly, you can comment on why you didn't repurchase any shares in the quarter?

We are aiming to take advantage of opportunities while also considering our overall capital allocation strategy. The market may not be progressing positively, but we still have about $300 million in debt on our plan, and we will maintain this approach. Historically, we have faced similar downturns when we were not active in the market. Typically, when we do enter the market, it is with larger amounts in specific quarters. Therefore, we will continue to take the same opportunistic approach that we have used in the past.

The next question comes from Jack Meehan of Nephron Research.

Wanted to start on capital allocation. Norman, just given the talk of a large deal, one of the top questions I've gotten from investors is succession planning at Bio-Rad. I personally really enjoy working with you. So I hope it's not soon, but is there any color you can just share with the investment community on long-term leadership plan for Bio-Rad? And if you were to do a deal that led to a much larger organization? Just how would you structure a leadership team to manage that?

Yes. Well, okay. So first, I think I've still got a few more years in me. So that's the #1. We do work on succession planning internally and have, I think, some good ideas around that. I think that in terms of structuring something, I think it really depends largely on what it is. And we have to kind of evaluate how it fits, how it needs to be managed. Over the last several years, of course, we've evolved into this kind of more what would I call it, a more functional organization. And that's allowed us to do a number of things and make a lot of progress. And again, I think it's time and situation dependent. Would we stay with that organization? Would we move to another kind of organization? Again, I think it's really all facts and circumstances.

Got it. And then on the business, Ilan or Andy, can you talk about like when you look at the backlog, just median time to deliver versus a normal period? Or is there a way to quantify how much larger sales would have been in the quarter if the supply chain issues didn't persist? I just look at the inventory, and we're talking about tens of millions of dollars, just any level of context would be helpful.

It's difficult to provide a clear answer. The delays are mostly related to interim platforms and electronic components, and the average delivery time is not particularly useful due to the wide variation connected to specific customers. Delivery can range from 6 weeks to several months. Over time, we have accumulated inventory as we await those final components, which our procurement team is actively trying to secure. It wouldn't be appropriate to speculate on what Q3 figures might have been, as focusing on that wouldn't give us a meaningful perspective with Q4 approaching.

Yes. And Jack, what I can say, I can confirm that it was definitely much higher than the order backlog that rolled over from last year to this year, so at the end of last year. Another indication that you can look at is the higher inventory level that's now we carry on the balance sheet. The incremental, a lot of it is in raw materials. So when it translates into revenue, so you get kind of an order of magnitude there of the kind of the opportunity, you can call it.

Got it. And then just the last one. Ilan, you mentioned the Russia business. I forgot if it was your Andy. Can you just remind us the size of the business for Bio-Rad and how that's performed this year? Is there a risk that you might be barred from selling to the country? Just how do you manage that?

Yes. I mean we have a team focused on deciphering and executing against this myriad of sanctions that come at us. More of the business in Russia for us is Clinical and Life Science. It's between 1% to 2% of sales. It fluctuates a bit in a typical year, and it is down a bit this year, as you might expect, more so on the Life Science side than on the Clinical side. We literally have a team that's focused on just interpreting every single sanction and whether it impacts us or not and can we load this truck as expected or not. It's not getting better, and it's difficult to know what it really will look like by the end of this year and moving into next year.

There are currently no additional questions registered at this time. We have a follow-up question from Brandon Couillard of Jefferies.

Ilan, since you quantified the interest income in the third quarter and then as we look at kind of $2 billion of cash on the balance sheet and move up in rates, you just talk about your cash, your capital allocation? And what would be a reasonable interest income rate to assume on that cash position out into next year?

Sure. Thank you, Brandon. Obviously, when we raised the last the bond with probably a great timing. Today, the treasury is above the coupon that we pay. It takes time to catch up. Specifically, if you think about the bonds, it was about $11 million of an expense for the quarter, and this specific quarter was about $8 million of interest income, but it continues to catch up as we will continue to roll the investments. So it should get within the next 1 to 2 quarters, assuming that these interest rates will continue to be out there, at least into kind of parity between the 2 could also be kind of moving into a gain there.

We have another follow-up question from Jack Meehan of Nephron Research.

So a couple of more business questions. Process media, I'm not sure if I missed in the script, but just can you give a magnitude of the growth in the quarter? And on top of discussion this earnings season, has been stocking dynamics with customers. Just are you seeing any of that? Just any color on inventory trends of customers would be helpful.

Yes. This is Simon. We saw high single-digit growth in process chromatography in the quarter, and we've been very conscious of the commentary elsewhere on stocking patterns. In our franchise, we haven't really been subject to supply chain challenges, and we've been able to assure our customers that will be delivering in a promised fashion. So we really haven't seen any noticeable change in ordering patterns or stocking from our customers, but we continue to watch it very closely, of course.

Great. And then on the diagnostics side, the two businesses that weren't called out, diabetes and autoimmune. Can you just talk about how they performed in the quarter if they declined, like what might have been contributing to that?

Yes. The main sort of headwinds there were just supply chain-related instrument placements. Those are both closed systems; consumables across the board continue to post good growth. It was really our impact of inability to fulfill instruments.

Got it. And then last one is on the China region in Diagnostics. I know it sounds like in the past, you've managed through the lockdown recently, but just talk about how the region performed any impact.

Sure. Very similar to sort of the conversation that we had last quarter in that there are two dynamics. The most material one is the larger supply constraint dynamic given the inability to fulfill instrumentation into China. And then the second was the periodic lockdowns, which have an impact on routine testing as well as an impact on logistics flow, just getting materials into the region. At a high level, though, demand remains strong. If we look at sort of the core clinical testing growth, it is demand is very much in line with pre-pandemic levels. The challenges really are these sort of circuit breaker events that just make the flow less than smooth over the last few quarters as well as the supply constrained headwinds that we're working through.

There are currently no additional questions registered at this time. So I'll pass the conference back over to the management team for closing remarks.

Yes. Thank you for joining today's call. We will be participating at the upcoming Crédit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California, in November, and hope to see some of you there. And as always, we appreciate your interest, and we look forward to connecting soon.

That concludes the conference call. Thank you for your participation. You may now disconnect your lines.